Everything below concerns lyophilization. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-20. Numbers and descriptions here follow the published literature rather than marketing material.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Derived from the seven-residue sequence |
| Molecular weight | About 751.9 g/mol | Average mass; the monoisotopic value is slightly lower |
| Residue count | Seven amino acids | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Parent compound | Tuftsin (Thr-Lys-Pro-Arg) | Selank extends tuftsin at the C-terminus |
| Compound class | Synthetic short peptide | Studied in a research setting; not a licensed drug in most markets |
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
The McDLT was a hamburger sold by the fast-food restaurant chain McDonald's from 1984 to 1991. The product's marketing focused on keeping the hot and cold components separate until the customer assembled them, popularized by the slogan "Keep the hot side hot, and the cool side cool." McDonald's discontinued the sandwich in early 1991, citing complaints about its bulky polystyrene packaging, which caused logistical difficulties in restaurant kitchens and environmental concerns. Later accounts have described the McDLT as a failed McDonald's product.
an identified market; and, a certain rate of consumption (demand) to maintain profit and outweigh perceived risks. Under these conditions competition is discouraged, ensuring criminal monopolies sustain profits. Legal substitution of goods or services may (by increasing competition) force the dynamic of organized criminal operations to adjust, as will deterrence measures (reducing demand), and the restriction of resources (controlling the ability to supply or produce to supply).
But the judge's ruling adds an additional $42.3 million, meaning the men will share about 17 percent of the money the whistle-blowers helped bring in. The total award, $52 million, is considered to be the largest whistleblower award to date.
=== Design for affinity === Protein–protein interactions are involved in most biotic processes. Many of the hardest-to-treat diseases, such as Alzheimer's disease, many forms of cancer (e.g., TP53), and human immunodeficiency virus (HIV) infection involve protein–protein interactions. Thus, to treat such diseases, it is desirable to design protein or protein-like therapeutics that bind one of the partners of the interaction and, thus, disrupt the disease-causing interaction. This requires designing protein-therapeutics for affinity toward its partner. Protein–protein interactions can be designed using protein design algorithms because the principles that rule protein stability also rule protein–protein binding. Protein–protein interaction design, however, presents challenges not commonly present in protein design. One of the most important challenges is that, in general, the interfaces between proteins are more polar than protein cores, and binding involves a tradeoff between desolvation and hydrogen bond formation. To overcome this challenge, Bruce Tidor and coworkers developed a method to improve the affinity of antibodies by focusing on electrostatic contributions. They found that, for the antibodies designed in the study, reducing the desolvation costs of the residues in the interface increased the affinity of the binding pair.
Sources: en.wikipedia.org
== Function == The protein encoded by this gene is one of two enzymes that transfers galactose moieties to hydroxylysine residues of collagen and mannose binding lectin. This gene is constitutively expressed and encodes a soluble protein that localizes to the endoplasmic reticulum.
=== Singles/EPs/demos === "Children Break" (1988) Barging Into the Presence of God EP (September 1989) UK Indie No. 3 UK No. 135 Half-Life EP (October 1990), 12" contains a bonus spoken-word track "Colour of the Sky" UK No. 86 "Kinky Love" (1991) (12" issued as Flesh Balloon EP) (June 1991) UK No. 72 "Porpoise" (1991) "Throwing Back the Apple" (May 1992) UK No. 93 Fine Friend EP (August 1994) "Fine Friend" (1994), US promo including "One Blue Hill" live acoustic @ KCRW "Angel (Will You Be My)" (1995), US promo
Leonian Gyoku Rou (レオン星人ギョク・ロウ, Reon Seijin Gyoku Rō): Ban's leonine predecessor, from Planet Leon, who was meant to become Deka Red on Earth, but was badly injured while protecting Jasmine and Hoji from an Alienizer called Terry X, which seemingly forced Rou to retire. In reality, he was tasked by Numa-O to go underground and prepare an elite team called the Fire Squad (ファイヤースクワッド, Faiyā Sukuwaddo). In the present, after being forced out of hiding when Terry X resurfaces, Rou recruits Ban in recognition of his fiery passion and drive for crime-fighting. Gyoku Rou is voiced by Daisuke Namikawa (浪川 大輔, Namikawa Daisuke).
=== TikTok Notes === In April 2024, TikTok users started receiving notifications that their current and future picture posts would be shown on a new app called TikTok Notes. The app was not released yet; however, TikTok confirmed it was being worked on. TikTok Notes was a direct competitor to Instagram for photo sharing. Jasmine Enberg, a principal social media analyst at eMarketer, observes that launching Notes as a separate app, instead of as a new feature in TikTok, may have been done in response to regulatory and consumer scrutiny. On 18 April 2024, Notes first released to users in Canada and Australia for limited testing. On 1 April 2025, it was announced that Notes would be shut down on 8 May. It went defunct on 8 May 2025.
=== Category:EC 2.8 (transfer sulfur-containing groups) === EC 2.8.1.1: Thiosulfate sulfurtransferase EC 2.8.1.2: 3-mercaptopyruvate sulfurtransferase EC 2.8.1.3: Thiosulfate—thiol sulfurtransferase EC 2.8.1.4: tRNA uracil 4-sulfurtransferase EC 2.8.1.5: Thiosulfate—dithiol sulfurtransferase EC 2.8.1.6: Biotin synthase EC 2.8.1.7: Cysteine desulfurase EC 2.8.1.8: Lipoyl synthase EC 2.8.1.9: Molybdenum cofactor sulfurtransferase EC 2.8.1.10: Thiazole synthase EC 2.8.1.11: Molybdopterin synthase sulfurtransferase EC 2.8.1.12: Molybdopterin synthase EC 2.8.1.13: tRNA-uridine 2-sulfurtransferase EC 2.8.1.14: tRNA-5-taurinomethyluridine 2-sulfurtransferase EC 2.8.1.15: tRNA-5-methyluridine(54) 2-sulfurtransferase
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.
Tuftsin contains four residues, while selank carries an additional Pro-Gly-Pro segment at the carboxyl end. That extension is intended to reduce enzymatic cleavage. Comparative pharmacokinetic data in humans remain limited.
No single receptor target is widely accepted as the definitive mediator of the reported effects. Proposed contributors include GABAergic modulation, shifts in monoamine turnover, and altered neuropeptide degradation. The mechanism is treated in the literature as unresolved.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.